To study FDC Dapagliflozin plus Bisoprol Fumarate, Eris Lifesciences receives approval from the CDSCO panel.

Published Date: 03 Jul 2023

New Delhi: The Central Drug Standard Control's Subject Expert Committee (SEC) has approved the waiver of the bioequivalence study.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot